Hypoparathyroidism News and Research

RSS
NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS announces data about hypoparathyroidism to be presented at ASBMR 2011 meeting

NPS submits NDA CMC section to FDA for GATTEX

NPS submits NDA CMC section to FDA for GATTEX

GSK, NPS enter agreement to evaluate ronacaleret in new indications

GSK, NPS enter agreement to evaluate ronacaleret in new indications

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

GATTEX Phase 3 study results in adult short bowel syndrome presented at DDW 2011

Nycomed submits teduglutide MAA to EMA for SBS treatment

Nycomed submits teduglutide MAA to EMA for SBS treatment

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

GATTEX Phase 3 pivotal study reaches primary efficacy endpoint of reducing PN in patients with SBS

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

NPS completes treatment phase in GATTEX Phase 3 registration study in short bowel syndrome

EDMA to endorse the campaign on Hypoparathyroidism

EDMA to endorse the campaign on Hypoparathyroidism

NPS third quarter net loss increases to $15.7 million

NPS third quarter net loss increases to $15.7 million

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

NPS Pharmaceuticals sells royalty rights from sales of REGPARA to DRI Capital's fund

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

NPS Pharmaceuticals supports second annual U.S. Rare Disease Day observance

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US

Validus chooses Ranbaxy to market an authorized generic version of Rocaltrol in the US